The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

7112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the safety of nitrous oxide (N2O) anaesthesia in patients with risk factors for coronary artery disease undergoing major surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ENIGMA - Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial

NCT00164047

Quality of Recovery From Anaesthesia Effects of Nitrous Oxide Following Anaesthesia Induced Endothelial Dysfunction

COMPLETED PHASE4

Physiological Effects of Nitrous Oxide on Anaesthesia

NCT01092923

Anesthesia

COMPLETED PHASE4

International Substudy Enigma2 on Postoperative Cognitive Disorders

NCT02489097

Anesthesia Delirium, Dementia, Amnestic, Cognitive Disorders

TERMINATED PHASE4

The Effect of N2O Administration on Arterial Oxygenation

NCT00146250

Anesthesia

COMPLETED PHASE4

Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial

NCT05991453

Surgery-Complications Anesthesia Complication Anesthesia Awareness +5 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 25% of patients undergoing major surgery have known coronary artery disease (CAD) or risk factors for CAD.

N2O interferes with vitamin B12 and folate metabolism. This impairs production of methionine (from homocysteine), used to form tetrahydrofolate and thymidine during DNA synthesis. It has been repeatedly demonstrated that N2O anaesthesia increases postoperative homocysteine levels. Chronic hyperhomocysteinaemia is associated with cardiovascular disease, and acute hyperhomocysteinaemia is known to cause endothelial dysfunction. One small trial has demonstrated an increased incidence of postoperative myocardial ischaemia in patients receiving N2O anaesthesia. Reducing postoperative myocardial infarction and death are important aims for those with CAD undergoing major surgery.

Our previous trial (ENIGMA) studied 2050 patients and identified some serious adverse effects, but most patients were not at risk of CAD and so we could not reliably assess serious cardiac complications. We propose a large simple randomized clinical trial of 7,000 patients to provide a definitive evaluation of the safety of N2O anaesthesia.

Updated statistical analysis plan can be found at www.enigma2.org.au.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

international, randomised, assessor-blinded trial in patients aged at least 45 years with known or suspected coronary artery disease having major non-cardiac surgery.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

The treating anaesthetist will be unblinded to the allocation. All other personnel (surgeon, participant and outcome assessor are all blinded to treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

70% Nitrous Oxide

General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%

Group Type OTHER

Nitrous Oxide

Intervention Type OTHER

General anaesthesia with the inclusion of Nitrous Oxide at 70%

No Nitrous Oxide

General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%

Group Type OTHER

No Nitrous Oxide

Intervention Type OTHER

General anaesthesia with no use of Nitrous Oxide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nitrous Oxide

General anaesthesia with the inclusion of Nitrous Oxide at 70%

Intervention Type OTHER

No Nitrous Oxide

General anaesthesia with no use of Nitrous Oxide

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult males and females age ≥ 45 years, undergoing noncardiac surgery and general anaesthesia expected to exceed two hours.
2. At increased risk of cardiac events, defined as any of

1. history of coronary artery disease as defined by a history of any one of the following: i. angina ii. MI iii. segmental wall motion abnormality on echocardiography or a fixed defect on radionuclide imaging iv. a positive exercise stress test for cardiac ischaemia v. a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test for cardiac ischaemia vi. coronary revascularization (CABG or PTCA) vii. angiographic evidence of atherosclerotic stenosis \> 50% of the diameter of any coronary artery viii. ECG with pathological Q waves in two contiguous leads
2. heart failure
3. cerebrovascular disease thought due to atherothrombotic disease
4. aortic or peripheral vascular disease
5. or three or more of the following risk factors:

* age ≥70 years
* any history of congestive heart failure
* diabetes and currently on an oral hypoglycaemic agent or insulin therapy
* current treatment for hypertension
* preoperative serum creatinine \>175 micro mol/L (\> 2.0 mg/dl)
* current or previous high cholesterol ≥6.2 mmol/L (\> 240 mg/dl)
* history of a transient ischemic attack (TIA) (i.e. a transient focal neurological deficit that lasted less than 24 hours and thought to be vascular in origin)
* emergency/urgent surgery (i.e. surgery which must be undertaken within 24 hours of acute presentation to hospital)
* high-risk type of surgery (i.e. intrathoracic or intraperitoneal)

Exclusion Criteria

1. having cardiac surgery
2. marked impairment of gas-exchange expected to require Fi02\> 0.5 intraoperatively
3. specific circumstances where N2O is contraindicated (eg. volvulus, pulmonary hypertension, raised intracranial pressure) or the anaesthetist plans to use supplemental oxygen (eg. colorectal surgery)
4. N2O unavailable for use.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No